Barclays highlights 3Q25 U.K. stock ideas: five "overweights," one "equal weight"
Inveting.com -- Barclays has released its U.K. equity strategy for the third quarter of 2025, highlighting five “overweight-rated” stocks and one “equal weight,” citing near-term catalysts and valuation upside.
The average potential return across the "overweight" picks is 24%, according to the bank’s price targets.
AstraZeneca (NASDAQ:AZN) tops the list with an expected upside of 32%. Barclays sees a key catalyst in the Phase 3 BaxHTN trial of baxdrostat, a potential treatment for uncontrolled hypertension.
The drug has demonstrated superior pharmacokinetic properties and aldosterone reduction compared with competitors.
The brokerage values the asset at GBp 259 per share, contributing to a price target of £140 for the stock, which trades at 15.4x 2025 earnings and 11.8x 2027 earnings.
Bellway (LON:BWY) is expected to deliver a 28% upside ahead of its October full-year results. Barclays anticipates a strategic shift from growth to return-focused capital allocation.
The brokerage projects return on invested capital to rise by 400bps to 8% by 2028, driven by a reduced landbank and improved cash generation.
The stock trades at 15.4x forward P/E for 2025 and is forecast to generate a net cash position of £652m by 2028.
Anglo American (JO:AGLJ), with a 21% upside, is undergoing restructuring after the recent demerger of Valterra. Barclays expects copper to drive 70% of group EBITDA by 2028–29.
The analysts notes that capex is forecast to fall by over 40% between 2025 and 2027, improving returns and capital efficiency. The stock trades at 6.6x EV/EBITDA for 2025 and 4.5x for 2027.
Unilever (LON:ULVR), which Barclays sees rising 20%, reports first-half results on July 31.
The brokerage expects a recovery in Asia and an acceleration in organic growth in the second half, citing effective pricing and marketing initiatives.
Barclays forecasts free cash flow to grow at 4.9% CAGR through 2027, with an equity FCF yield rising to 6.1% in that year. The stock trades at 17.8x 2025 earnings.
Lloyds Banking Group (LON:LLOY) has an 18% expected upside. A ruling from the U.K. Supreme Court on motor finance commissions could unlock provision releases, potentially narrowing Lloyds’ valuation discount.
Barclays estimates EPS growth of 60% from 2025 to 2027, supported by rising income and capital distributions totaling over 40% of market cap.
The bank assigns a price target of 90p, with the stock trading at 7.5x 2026 earnings and 6.3x 2027 earnings.
SEGRO, rated “equal weight,” offers 6% upside. Barclays remains cautious ahead of the July 31 half-year results, citing weak leasing performance and the potential for reduced capital expenditure.
The company’s projected 3% EPS CAGR lags peers, and it trades at 18.6x 2025 P/E.
With LLOY making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed LLOY alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including LLOY, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is LLOY poised for similar growth? Don't miss the opportunity to find out.
